RHI Magnesita India Ltd
RHI Magnestia India ltd earlier known as Orient Refractories Limited (ORL) is in the business of manufacturing and marketing special refractory products, systems
and services to the steel industry in India and Globally. It is a market leader for special refractories in India and has many global customers for its international quality products.[1]
- Market Cap ₹ 10,535 Cr.
- Current Price ₹ 510
- High / Low ₹ 830 / 490
- Stock P/E 52.9
- Book Value ₹ 189
- Dividend Yield 0.49 %
- ROCE 8.58 %
- ROE 9.58 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has a low return on equity of 13.9% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Refractories Industry: Refractories / Intermediates
Part of BSE 250 SmallCap Index Nifty 500 Multicap 50:25:25 BSE Industrials BSE 400 MidSmallCap Index BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
748 | 1,388 | 1,370 | 1,999 | 2,726 | 3,781 | 3,612 | |
619 | 1,172 | 1,161 | 1,610 | 2,365 | 3,227 | 3,086 | |
Operating Profit | 129 | 215 | 209 | 390 | 361 | 555 | 526 |
OPM % | 17% | 16% | 15% | 19% | 13% | 15% | 15% |
18 | 10 | 12 | 5 | -646 | -322 | -302 | |
Interest | 1 | 14 | 7 | 3 | 40 | 65 | 50 |
Depreciation | 9 | 26 | 30 | 34 | 71 | 182 | 191 |
Profit before tax | 138 | 186 | 185 | 357 | -396 | -16 | -17 |
Tax % | 35% | 27% | 26% | 25% | 18% | 545% | |
90 | 136 | 137 | 269 | -466 | -100 | -100 | |
EPS in Rs | 7.48 | 11.31 | 11.37 | 16.71 | -24.79 | -4.86 | -4.83 |
Dividend Payout % | 33% | 22% | 22% | 15% | -10% | -51% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 38% |
3 Years: | 40% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 29% |
3 Years: | 33% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 19% |
3 Years: | 15% |
1 Year: | -31% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 14% |
Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 16 | 19 | 21 | 21 |
Reserves | 364 | 691 | 794 | 1,013 | 2,872 | 3,825 | 3,892 |
0 | 71 | 62 | 65 | 1,589 | 487 | 453 | |
132 | 278 | 391 | 581 | 1,400 | 765 | 958 | |
Total Liabilities | 508 | 1,052 | 1,260 | 1,674 | 5,881 | 5,097 | 5,324 |
60 | 228 | 243 | 282 | 3,258 | 2,805 | 2,782 | |
CWIP | 3 | 9 | 46 | 34 | 39 | 49 | 53 |
Investments | 103 | 0 | 0 | 0 | 0 | 0 | 0 |
342 | 816 | 970 | 1,358 | 2,583 | 2,244 | 2,488 | |
Total Assets | 508 | 1,052 | 1,260 | 1,674 | 5,881 | 5,097 | 5,324 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
54 | 173 | 165 | 27 | 238 | 271 | |
-5 | 26 | -79 | -70 | -1,150 | -312 | |
-35 | -118 | -54 | -50 | 1,172 | -231 | |
Net Cash Flow | 14 | 81 | 33 | -93 | 260 | -272 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 77 | 87 | 87 | 89 | 101 | 79 |
Inventory Days | 96 | 117 | 151 | 186 | 204 | 148 |
Days Payable | 92 | 99 | 148 | 161 | 180 | 95 |
Cash Conversion Cycle | 82 | 105 | 90 | 114 | 125 | 131 |
Working Capital Days | 87 | 105 | 108 | 124 | 130 | 135 |
ROCE % | 35% | 23% | 37% | 11% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Nov - Transcript of Q2 FY2025 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Cessation
12 Nov - Dr. Vijay Sharma ceases as Independent Director.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Nov - Dr. Vijay Sharma ceases as Independent Director.
-
Corrigendum - Intimation Of Completion Of Tenure Of Independent Director Of The Company, Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
12 Nov - Dr. Vijay Sharma ceases as Independent Director; Parmod Sagar becomes Chairman.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Nov - Dr. Vijay Sharma ceases as Independent Director.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
Market Leadership
The company is the leading global manufacturer and supplier of high-grade refractory products, systems, and solutions with a 30% market share in India. [1]